Immunohistochemical Expression of bcl 2 and Ki-67 in Thyroid Neoplasms
DOI:
https://doi.org/10.21276/apalm.3647Keywords:
Immunohistochemistry, bcl 2, Ki-67Abstract
Background: Thyroid cancer is the most common endocrine cancer today. Its inci- dence has increased all over the world in the last three decades. An accurate diagnosis of thyroid neoplasm is therefore crucial as it has a major impact on the treatment modality as well as the patient's prognosis. This study was being done to determine utility expression of bel 2 and Ki-67 in thyroid neoplasms.
Methods: This cross sectional study was conducted in the Department of Pathology at Bhagat Phool Singh Government Medical College for Women, Khnapur Kalan, Sonipat, Haryana. A total of 55 specimens were subjected to IHC (bel 2 and Ki-67).
Results: Out of 55 thyroid neoplasm cases, 27 were benign and 28 were malignant. All the neoplastic pathologies showed varying degree of bel 2 positive expression. Ki-67 was negative in all benign neoplasms. Varying degree of positive expression was seen in malignant neoplasms: 100% positivity in follicular thyroid carcinoma (04/04), followed by 50% cases of invasive encapsulated follicular variant of papillary thyroid carcinoma (03/06), followed by 33.33% cases of papillary thyroid carcinoma (05/15). The expression of bel 2 was found to have 50.00% sensitivity and 33.33% specificity in thyroid neoplasms with diagnostic accuracy of 49.09%. The expression of Ki-67 was found to have 98% sensitivity and 67.50% specificity in detecting malignant thyroid neoplasms with diagnostic accuracy of 76.36%.
Conclusion: Ki-67 proved to be useful marker in differentiating malignant thyroid neoplasms from the benign one as the Ki-67 labelling index more in the malignant neoplasms, it was statistically significant. The other IHC marker studied in the present study was bel 2 which acted as marker of proliferation for thyroid tissue, can help in detecting the metastatic foci in other organs and to diagnose the cases of poorly differentiated thyroid carcinomas.
References
1. Pujani M, Arora B, Singh SK, Tejwani N. Role of Ki-67 as a proliferative marker in lesions of thyroid. Indian J Cancer. 2010;47(3):304-7.
2. Agarwal S, Bychkov A, Jung CK. Emerging biomarkers in thyroid practice and research. Cancers. 2022:14(1):204.
3. Knox MA. Thyroid nodules. Am Fam Physician. 2013:88:193-6.
4. Santosh UP, Sunil Kumar KB. Trupthi MC, Boobalan S. A comprehensive approach to thyroid swellings: clinical, sonological, cytological and histopathological correlation. Int J Otorhinolaryngol Clin. 2014;6(2):28-31.
5. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2022). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://geo.iarc.who.int/today, accessed 11/02/2025.
6. Rezk S. Khan A. Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma. Appl Immunohistochem Mol Morphol. 2005;13:256-64.
7. Bozec A, Ilie M, Lassalle S, Hofman V, Benaim G, Long E, Santini J, Hofman P. Usefulness of ancillary methods for diagnosis, prognosis and targeted therapy in thyroid pathology. Curr Med Chem. 2013;20(5):639-54.
8. Hockenbury D. Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane that blocks programmed cell death. Nature. 1990:348:334-6.
9. Dzulkifli FA, Mashor MY, Jaafar H. An overview of recent counting methods for Ki67 IHC staining. J Biomed Clin Sci. 2019:3:10-7.
10. Zhou Y, Jiang HG, Lu N, Lu BH, Chen ZH. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. Asian Pac J Cancer Prev. 2015 16(4):1605-8.
11. Yorukoglu A, Yalcin N, Avci A, Cakalagaoglu F, Yaylali G, Akin F, Haciyanli M. Significance of IMP3, nucleophosmin, and Ki-67 expression in papillary thyroid carcinoma. Ann Diagn Pathol. 2014;18(6):357-62.
12. Bakshi J, Patro SK, Kaur N, Panda NK, Budhiraja G. Understanding malignancies of the thyroid gland: Institutional experience. Indian J Otolaryngol Head Neck Surg. 2018:70(4):482-9.
13. Goyal D. Negi SR, Sajid A, Ahuja P. Histopathological spectrum of thyroid lesions at tertiary care hospital in Western Rajasthan. Asian J Pharm Clin Res. 2023;16(10):2455-91.
14. Bhandari H. Sharma A, Nilapwar RD, Vyas PG, Pawar AS. Histopathological spectrum of thyroid neoplasm - A retrospective study done at tertiary cancer care hospital. Int J Sci Healthc Res. 2024;9(1):21-30.
15. Chowdhury R, Alsayegh R, Forest VI, Pusztaszeri MP, da Silva SD, Florianova L. Payne RJ. Ki-67 labelling index as a predictor of invasive features in thyroid cancer: retrospective analysis and implications. Curr Oncol. 2024;31(7):4030-7.
16. Aksoy M, Tezelman S, Erhan Y, Onaran Y, Aydin S. Expression of bel-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg. 2005;105(6):626-30.
17. Gharrrawi SAR, Alkhafaji HMA, Naji RZ. Immunohistochemical Expression of CD68, p53 and bel2 in thyroid tumors. Indian J Forensic Med Tox. 2020;14(1):1260-6.
18. Akgün GA, Temiz P, Ayhan S, Duman FU, Aydede H. Microarray analysis of cell cycle and apoptosis biomarkers (p16, p21, p27, p53, bcl2, Bax, Bcl-xL and Cyclin D1) in thyroid papillary carcinoma, papillary microcarcinoma and lymph node metastasis of thyroid papillary carcinoma. Cel bay uni sa bil ent derg. 2021; 8(3): 419-25.
19. Sharma A, Singh J, Chahal KS, Paul S, Neki NS. Diagnostic utility of Ki-67 as a proliferative marker & the expression of Galectin-3 in Neoplastic and Non-neoplastic lesions of thyroid. Int J Curr Res Med Sci. 2018;4(12):19-26.
20. Sharma A. Singh J, Chahal KS, Paul S, Neki NS. Diagnostic utility of Ki-67 as a proliferative marker & the expression of Galectin-3 in Neoplastic and Non-neoplastic lesions of thyroid. Int J Curr Res Med Sci. 2018;4(12):19-26.
21. Zhou Y, Jiang HG, Lu N, Lu BH, Chen ZH. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. Asian Pac J Cancer Prev. 2015 16(4):1605-8.
22. Song Q, Wang D, Lou Y, Li C, Fang C, He X, Li J. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 2011;6:126.
23. Dwivedi SS, Khandeparkar SGS, Joshi AR, Kulkarni MM, Bhayekar P, Jadhav A, et al. Study of immunohistochemical markers (CK-19, CD-56, Ki-67, p53) in differentiating benign and malignant solitary thyroid nodules with special reference to papillary thyroid carcinomas. J Clin Diagn Res. 2016;10(12):14-9.
24. Hellgren LS, Stenman A, Paulsson JO, Höög A, Larsson C, Zedenius J, Juhlin CC. Prognostic utility of the Ki-67 labeling index in follicular thyroid tumors: a 20-year experience from a tertiary thyroid center. Endocr Pathol. 2022:33:231-42.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Vijyendra Puri Goswami, Swaran Kaur, Monika B Gathwal, Sunaina Hooda, Tanu Priya Sheoran
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
